NR565 | NR565 Advanced Pharmacology
Fundamentals Exam 1 v3 | Questions with Correct
Answers and Expert Explanation for Each Question
| Chamberlain
1. Which phase of pharmacokinetics is most affected by the ‘first-pass’ effect when a
drug is administered orally?
A. Distribution
B. Excretion
C. Absorption
D. Metabolism
Correct Answer: D
Expert Explanation: The first-pass effect occurs when a drug is metabolized by the
liver before it reaches the systemic circulation. This significantly reduces the
bioavailability of certain oral medications compared to other routes. Understanding
this process is essential for calculating appropriate oral dosages to ensure
therapeutic efficacy.
2. A patient has a low serum albumin level. How does this affect the distribution of a
highly protein-bound drug?
A. The drug becomes more concentrated in the liver
,B. The drug is excreted more slowly by the kidneys
C. There is an increase in the free, active fraction of the drug
D. The drug becomes permanently inactivated
Correct Answer: C
Expert Explanation: Low albumin levels result in fewer binding sites for highly
protein-bound medications. This leads to an increase in the free or unbound fraction
of the drug, which is the pharmacologically active form. Providers must monitor for
potential toxicity in patients with hypoalbuminemia when prescribing medications
like warfarin or phenytoin.
3. Which of the following describes a drug that binds to a receptor and produces a
maximal response?
A. Full Agonist
B. Competitive Antagonist
C. Partial Agonist
D. Inverse Agonist
Correct Answer: A
Expert Explanation: A full agonist binds to a receptor and mimics the endogenous
ligand to produce a maximum biological response. This differs from a partial
,agonist, which can only produce a submaximal response regardless of the dose.
Clinicians select agonists based on the desired intensity of the physiological effect
required for treatment.
4. How many half-lives are generally required for a drug to reach steady-state
concentration in the body?
A. 4 to 5 half-lives
B. 1 to 2 half-lives
C. 8 to 10 half-lives
D. Steady state is reached immediately
Correct Answer: A
Expert Explanation: Steady state is achieved when the rate of drug administration
equals the rate of drug elimination. It typically takes between four and five half-lives
for a drug to reach a consistent therapeutic level in the plasma. This principle helps
providers determine when to draw blood levels for therapeutic drug monitoring.
5. In the United States, which agency is responsible for regulating the manufacture
and distribution of controlled substances?
A. Food and Drug Administration (FDA)
B. Drug Enforcement Administration (DEA)
, C. Department of Health and Human Services (HHS)
D. The State Board of Nursing
Correct Answer: B
Expert Explanation: The Drug Enforcement Administration (DEA) enforces the
Controlled Substances Act to prevent the diversion of illicit drugs. While the FDA
approves drugs for safety and efficacy, the DEA specifically manages the legal
requirements for prescribing controlled substances. Providers must maintain a DEA
registration to prescribe drugs listed in Schedules II through V.
6. A drug that is a CYP450 3A4 ‘inhibitor’ will likely have what effect on a co-
administered substrate of the same enzyme?
A. Decrease the substrate’s plasma concentration
B. Have no effect on the substrate’s metabolism
C. Increase the substrate’s plasma concentration
D. Increase the rate of the substrate’s excretion
Correct Answer: C
Expert Explanation: CYP450 inhibitors slow down the metabolism of other drugs
that are processed by the same enzyme system. This leads to higher-than-expected
plasma concentrations of the substrate drug, increasing the risk of adverse reactions
Fundamentals Exam 1 v3 | Questions with Correct
Answers and Expert Explanation for Each Question
| Chamberlain
1. Which phase of pharmacokinetics is most affected by the ‘first-pass’ effect when a
drug is administered orally?
A. Distribution
B. Excretion
C. Absorption
D. Metabolism
Correct Answer: D
Expert Explanation: The first-pass effect occurs when a drug is metabolized by the
liver before it reaches the systemic circulation. This significantly reduces the
bioavailability of certain oral medications compared to other routes. Understanding
this process is essential for calculating appropriate oral dosages to ensure
therapeutic efficacy.
2. A patient has a low serum albumin level. How does this affect the distribution of a
highly protein-bound drug?
A. The drug becomes more concentrated in the liver
,B. The drug is excreted more slowly by the kidneys
C. There is an increase in the free, active fraction of the drug
D. The drug becomes permanently inactivated
Correct Answer: C
Expert Explanation: Low albumin levels result in fewer binding sites for highly
protein-bound medications. This leads to an increase in the free or unbound fraction
of the drug, which is the pharmacologically active form. Providers must monitor for
potential toxicity in patients with hypoalbuminemia when prescribing medications
like warfarin or phenytoin.
3. Which of the following describes a drug that binds to a receptor and produces a
maximal response?
A. Full Agonist
B. Competitive Antagonist
C. Partial Agonist
D. Inverse Agonist
Correct Answer: A
Expert Explanation: A full agonist binds to a receptor and mimics the endogenous
ligand to produce a maximum biological response. This differs from a partial
,agonist, which can only produce a submaximal response regardless of the dose.
Clinicians select agonists based on the desired intensity of the physiological effect
required for treatment.
4. How many half-lives are generally required for a drug to reach steady-state
concentration in the body?
A. 4 to 5 half-lives
B. 1 to 2 half-lives
C. 8 to 10 half-lives
D. Steady state is reached immediately
Correct Answer: A
Expert Explanation: Steady state is achieved when the rate of drug administration
equals the rate of drug elimination. It typically takes between four and five half-lives
for a drug to reach a consistent therapeutic level in the plasma. This principle helps
providers determine when to draw blood levels for therapeutic drug monitoring.
5. In the United States, which agency is responsible for regulating the manufacture
and distribution of controlled substances?
A. Food and Drug Administration (FDA)
B. Drug Enforcement Administration (DEA)
, C. Department of Health and Human Services (HHS)
D. The State Board of Nursing
Correct Answer: B
Expert Explanation: The Drug Enforcement Administration (DEA) enforces the
Controlled Substances Act to prevent the diversion of illicit drugs. While the FDA
approves drugs for safety and efficacy, the DEA specifically manages the legal
requirements for prescribing controlled substances. Providers must maintain a DEA
registration to prescribe drugs listed in Schedules II through V.
6. A drug that is a CYP450 3A4 ‘inhibitor’ will likely have what effect on a co-
administered substrate of the same enzyme?
A. Decrease the substrate’s plasma concentration
B. Have no effect on the substrate’s metabolism
C. Increase the substrate’s plasma concentration
D. Increase the rate of the substrate’s excretion
Correct Answer: C
Expert Explanation: CYP450 inhibitors slow down the metabolism of other drugs
that are processed by the same enzyme system. This leads to higher-than-expected
plasma concentrations of the substrate drug, increasing the risk of adverse reactions
